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In this paper, the human phosphodiesterase 7A1 (hPDE7A1)
promoter region was identified and functionally characterized.
Transient transfection experiments indicated that a 2.9 kb frag-
ment of the hPDE7A1 5′-flanking region, to position − 2907,
has strong promoter activity in Jurkat T-cells. Deletion analysis
showed that the proximal region, up to position − 988, contains
major cis-regulatory elements of the hPDE7A1 promoter. This
minimal promoter region contains a regulatory CpG island which
is essential for promoter activity. The CpG island contains
three potential cAMP-response-element-binding protein (CREB)-
binding sites that, as judged by in vivo dimethyl sulphate (DMS)
footprinting, are occupied in Jurkat T-cells. Moreover, over-
expression of CREB results in increased promoter activity, but,
on the other hand, promoter activity decreases when a dominant-
negative form of CREB (KCREB) is over-expressed. In vivo DMS
footprinting strongly indicates that other transcription factors,
such Ets-2, nuclear factor of activated T-cells 1 (NFAT-1) and
nuclear factor κB (NF-κB), might also contribute to the regulation
of hPDE7A1 promoter. Finally, hPDE7A1 promoter was found
to be induced by treatment with PMA, but not by treatment
with dibutyryl cAMP or forskolin. These results provide insights
into the factors and mechanisms that regulate expression of the
hPDE7A gene.
Key words: cAMP, cAMP-response-element-binding protein
(CREB), CpG island, phorbol ester, transcription.
INTRODUCTION
Signalling by cyclic nucleotides is a major signal-transduction
pathway in eukaryotes. A remarkable aspect of this signal-
ling pathway is the large number of closely related proteins acting
at each step of the transduction cascade. This is particularly so at
the level of the cyclic nucleotide phosphodiesterases (PDEs), the
enzymes involved in the hydrolysis of cAMP and/or cGMP (for
reviews see [1,2]). Mammalian PDEs are encoded by at least
19 different genes that, through alternative splicing and differ-
ential transcription regulation, give rise to many more variants
(> 50). The various isoforms and variants differ in their en-
zymic properties, cellular localization and sensitivity to signals.
The large number of PDEs probably reflects that a precise regu-
lation of the intracellular levels of cyclic nucleotides is of
critical importance for multiple cellular processes. The specific
physiological roles played by the different PDEs are, however,
largely unknown. There is abundant experimental evidence indi-
cating that expression of PDEs is regulated during development
and differentiation [1]. The contribution of alternative splicing to
the generation of variants has been documented extensively, but,
on the other hand, very little is known about the regulation of
PDE expression at the transcriptional level. The complex patt-
erns of expression of the PDE genes strongly suggest that a
number of developmental, hormonal, signal-induced and tissue-
specific factors must be involved in regulating transcription of
the PDE genes. However, most of the actual transcription factors
and regulatory circuits controlling expression of the PDE genes
are still unknown, as identification of the corresponding promoter
regions has been reported for only very few PDE genes (PDE3B,
PDE4D, PDE5A and PDE6A) [3–7].
In this paper, the identification and characterization of the
human PDE7A1 (hPDE7A1) promoter region is reported. Three
hPDE7A variants have been described (hPDE7A1, hPDE7A2
and hPDE7A3) that are differentially expressed in some tissues
Abbreviations used: CRE, cAMP-response element; CREB, cAMP-response-element-binding protein; NFAT-1, nuclear factor of activated T-cells 1; NF-κB,
nuclear factor κB; DMS, dimethyl sulphate; PDE, phosphodiesterase; h, human; RACE, rapid amplification of cDNA ends; db-cAMP, dibutyryl cAMP; PKA,
protein kinase A; PKC, protein kinase C.
1 To whom correspondence should be addressed (e-mail fambmc@cid.csic.es).
[8–11]. hPDE7A1 is highly expressed in tissues of the immune
system as well as in several T- and B-cell lines [8,11]. Moreover,
in human T-cells, expression of hPDE7A1 is induced following
CD3/CD28 co-stimulation and is required for T-cell activation
[12]. Similarly, hPDE7A3 is also up-regulated upon T-cell
activation [9]. On the other hand, in the adult, expression of
hPDE7A2 appears mostly restricted to skeletal muscle and heart
[8,10,11]. In this paper we show that a DNA fragment containing
2.9 kb of the 5′ region flanking the transcription start site of
hPDE7A1 has strong promoter activity in transient-transfection
experiments performed in Jurkat T-cells. Deletion analysis
indicates that the proximal region, up to position − 988, retains
most of the promoter activity. This minimal promoter region
has all the characteristic features of a functional CpG island,
is induced by treatment with PMA and contains three functional
cAMP-response-element-binding protein (CREB)-binding sites.
The CpG island also contains binding sites for other transcription
factors [Ets-2, nuclear factor of activated T-cells 1 (NFAT-1) and
nuclear factor κB (NF-κB)] that, as judged by in vivo dimethyl-
sulphate (DMS) footprinting, are likely to participate in the
regulation of hPDE7A1 transcription.
EXPERIMENTAL
Cloning and sequencing of the hPDE7A1 5′-flanking region
To clone the hPDE7A1 5′-flanking region, a human BAC library
(Genome System, St. Louis, MO, U.S.A.) was screened with
a 32P-labelled specific probe spanning nucleotide positions 69–
796 of the hPDE7A1 cDNA (GenBank R© accession no. L12052).
Two positive clones, carrying 150–200-kb-long inserts, were
obtained. One clone, which contained exon 1, was selected and
used to obtain a shotgun library of 3-kb inserts (GATC-Biotech
AG, Konstanz, Germany). Screening of the shotgun library was
c© 2003 Biochemical Society
836 M. Torras-Llort and F. Azor´ın
Figure 1 Genomic organization of the hPDE7A locus
(A) Schematic representation of the exon/intron structure of the three hPDE7A variants (hPDE7A1, hPDE7A2 and hPDE7A3). Exons are numbered and shown as vertical bars. (B) Nucleotide sequence
of the 5′-flanking region of hPDE7A1 (EMBL accession no. AJ457788). The sequence from position − 2908 to + 592 is shown. The +1 position corresponds to the mapped transcriptional start
site (GenBank accession no. L12052). The position of the ATG codon is marked by an arrow, and sequence translation for the first exon is given. Lower-case letters indicate intron sequences. The
positions of some relevant potential binding sites for transcription factors are shown by boxes. Cleavage sites for some restriction enzymes are also indicated.
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performed by PCR using primers derived from the sequence of
exon 1. Positive clones were then sequenced and new primers
were derived from the determined sequence. The process was
reiterated to cover the 5′-flanking region up to position −4137.
5′ Rapid amplification of cDNA ends (RACE) experiments
To obtain full-length 5′ ends of hPDE7A1/A3 cDNAs, 5′ RACE
experiments were performed from total Jurkat RNA with a
Gene RacerTM kit (Invitrogen) in accordance with the manufac-
turer’s instructions. In these experiments, several primers derived
from the sequence of the 5′ region common to hPDE7A1 and
hPDE7A3 (GenBank accession no. AF332652), were used: 5′-
GTAACATCCGCAGCGTGG-3′ (nucleotides 712–695), 5′-GG-
GAATTTGAAACCGCAGTACCAC-3′ (nucleotides 447–424),
5′-GCTGATGGCTCCTCGGCGGCTG-3′ (nucleotides 134–113)
and 5′-CATTGAATACGCCCGCCCTGCC-3′ (nucleotides 53–
32; sequence co-ordinates are derived from GenBank accession
no. L12052). RACE products were cloned into a pGEM-T Easy
vector (Promega) and sequenced.
Computer-aided analysis of potential CpG islands
Prediction of putative CpG islands was performed by using
CpG finder at the European Bioinformatics Institute (EMBL;
http://www.ebi.ac.uk/). The parameters defined were: CpG length
>200 bp, G + C >50% and a ‘CpG value’ (the ratio of observed
to expected frequencies of the CpG dinucleotide) of at least 0.6.
The resulting putative CpG islands were merged if they were
within 100 bp of each other and if the CpG value of the merged
island was still higher than 0.6.
Southern-blot analysis
Genomic DNA was obtained from Jurkat T-cells by the proteinase
K digestion method. Genomic DNA (30 µg) was digested with
BamHI, BamHI + HpaII or BamHI + MspI. Digested DNAs were
then analysed by electrophoresis on 0.8% agarose/Tris/borate/
EDTA gels, transferred to nylon and hybridized with a randomly
labelled 32P probe spanning nucleotides −1425 to −290 of the
hPDE7A 5′-flanking region.
Determination of the patterns of DNA methylation
DNA methylation at cytosine residues was determined by the
bisulphite-conversion reaction [13]. Genomic DNA from Jurkat
T-cells (10 µg) was digested with BamHI + PvuII, denatured by
treatment with 0.3 M NaOH for 30 min at 37 ◦C and incubated at
55 ◦C for 16 h in 3.1 M sodium bisulphite/0.5 mM hydroquinone.
Modified DNAs were amplified by two rounds of PCR using
nested primers. PCR products were purified by gel electrophoresis
and sequenced.
Determination of promoter activity
Promoter activity was determined by transient-transfection exper-
iments performed in Jurkat T-cells using a luciferase reporter
system. For this purpose, a 2.9-kb DNA fragment of the
hPDE7A 5′-flanking region (positions −6 to −2907) was fused
to the promoter-less firefly luciferase gene of plasmid pGL3b
(Promega). 5′ and 3′ deletions of this 2.9-kb fragment were
obtained by cleavage with appropriate restriction enzymes. The
Figure 2 The proximal region of the 5′-flanking region of hPDE7A1 contains
a CpG island
(A) Distribution of the CpG dinucleotide through the hPDE7A1 5′-flanking region. Vertical lines
represent CpG dinucleotides. The box indicates the position of exon 1 and the arrow indicates
the position of the ATG codon. Cleavage sites for some restriction enzymes are indicated (A,
Aat II; B, BamHI; E, EcoRI; H, HindIII; K, KpnI; S, SpeI). (B) Distribution of the CpG value through
this region. CpG value, expressed as the ratio of observed to expected frequencies of the CpG
dinucleotide, was determined using CpG finder at the European Bioinformatics Institute. Only
values higher than 0.9 are represented. The position of the ATG codon is shown by the dotted
line. (C) Southern-blot analysis of the patterns of cleavage by MspI and HpaII at the hPDE7A1
5′-flanking region. The distribution of MspI/HpaII restriction sites through this region is shown
schematically. The position of the first exon (box), the ATG codon (arrow) and the two BamHI
restriction sites (B) flanking this region are indicated. The probe used in this analysis is also
indicated (dotted line). The patterns of cleavage by BamHI (lanes 1 and 4), BamHI + HpaII
(lanes 2 and 5) and BamHI + MspI (lanes 3 and 6) of genomic DNA obtained from Jurkat
T-cells (lanes 4–6) and of a BAC clone carrying the hPDE7A genomic region (lines 1–3) are
presented. Numbers on the left indicate appropriate molecular-mass markers.
various promoter constructs assayed are summarized in Figure 3
(see below). For transient-transfection analysis, Jurkat T-cells
were grown in Dulbecco’s modified Eagle’s medium supple-
mented with 10% foetal calf serum, 2 mM L-glutamine, 100 µg/
ml streptomycin and 100 units/ml penicillin. Prior to trans-
fection, cells were washed with non-supplemented Dulbecco’s
modified Eagle’s medium, resuspended in serum-free medium
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Figure 3 Pattern of CpG methylation through the CpG island (position −1200 to +100) as determined by the bisulphite-conversion reaction
Empty circles are unmethylated cytosines. Half and full circles indicate, respectively, partially methylated and fully methylated residues. nd, not determined.
at a density of 40 × 106 cells/ml and transfected by electro-
poration (250 V, 950 µF) with 15 µg of the corresponding pGL3b
plasmid. To normalize for changes in transfection efficiency, 3 µg
of pRL-TK vector, expressing Renilla luciferase under the con-
trol of the thymidine kinase promoter, was always co-transfected
together with the pGL3b plasmids. After electroporation, cells
were split into 3-ml aliquots (1 × 106 cells/ml) and grown for 48 h
before determination of luciferase activities. Luciferase activities
were determined by the dual-luciferase assay system (Promega),
according to the manufacturer’s instructions. Treatment with
PMA or dibutyryl-cAMP (db-cAMP) was performed 24 h after
transfection by growing the cells in the presence of 20 nM PMA
for 24 h or in 2 mM db-cAMP for 12–24 h before determination
of the luciferase activities.
When CREB, KCREB (a dominant-negative mutant form of
CREB) or the catalytic subunit of protein kinase A (PKA)
was over-expressed, plasmids RSV-CREB, RSV-KCREB and
SRα-PKA were used [14,15]. Increasing amounts of the
corresponding plasmids were transfected into Jurkat T-cells by
electroporation together with 5 µg of either −1.4PDE7A or
−0.98PDE7A promoter constructs. To normalize for changes in
transfection efficiency, 1 µg of pRL-TK (SRα-PKA) or CMV-β-
gal, expressing LacZ under the control of the cytomegalovirus
promoter, RSV-CREB and RSV-KCREB was added to the
transfection. Total DNA concentration was adjusted to 20 µg
by the addition of pUC19. Cells were harvested 24 h post-
transfection and processed as described above.
In vivo DMS footprinting
For in vivo DMS footprinting, exponentially growing Jurkat
T-cells (107–108) were harvested, washed twice with PBS and
treated with 0.1% DMS for 5 min at room temperature. The
reaction was stopped by the addition of 100 mM β-mercapto-
ethanol in PBS. Cells were then washed with cold PBS and
incubated at 50 ◦C for at least 3 h in 100 mM NaCl, 10 mM
Tris/HCl (pH 8), 25 mM EDTA, 0.5% SDS and 0.2 mg/ml
proteinase K. When the reaction was performed with naked DNA,
10 µg of purified genomic DNA from Jurkat T-cells was treated
with 0.5% DMS for 4 min at room temperature. After DMS
treatment, DNAs were purified and cleaved by treatment with
1 M piperidine at 90 ◦C for 30 min. The patterns of DMS cleavage
were then determined by ligation-mediated PCR as described in
[16].
RESULTS AND DISCUSSION
The proximal region of the hPDE7A1 5′-flanking region
contains a CpG island
Figure 1(A) shows the genomic organization of the hPDE7A
gene which is located at chromosomal position 8q13 [17]. The
coding region spans 124 kb and contains 14 exons. The hPDE7A2
isoform starts at exon 2, which is spliced out in the hPDE7A1 and
hPDE7A3 isoforms. The current version of the freely accessible
Celera (http://public.celera.com/humanpub/index.jsp) sequence
of the human genome covers most of the PDE7A locus (genomic
scaffold segment GA x2HTBL474CD:1.500000), but contains a
gap of approx. 2.5 kb that includes part of the first intron, the first
exon and approx. 1.5 kb of the 5′-flanking sequence. The database
of the Public Consortium (http://www.ensembl.org/Homo
sapiens/) contains a larger gap in this region (EMBL accession
no. AC055822). This gap was covered by four overlapping clones
obtained as described in the Experimental section, and the region
from position −5169 to +1700 was sequenced (EMBL accession
no. AJ457788). Figure 1(B) shows the nucleotide sequence of this
region from position −2908 to position +592.
The longest reported hPDE7A1 cDNA (GenBank accession
no. L12052) shows an unusually short 5′-untranslated region,
only 50 bp long (Figure 1B). This result was confirmed in 5′
RACE experiments using different oligonucleotides derived from
the sequence of the 5′ region of the hPDE7A1 cDNA (see the
Experimental section for a detailed description of the primers
used). Consistent with these results, the 5′ region immediately
flanking the mapped +1 position of hPDE7A1 shares several
features which strongly suggest that it corresponds to a cis-
regulatory region. On one hand, it contains potential binding
sites for several transcription factors (Figure 1B) that are likely
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to participate in regulating the expression of hPDE7A1 (see
below). Secondly, although the most proximal region carries no
identifiable TATA-box sequence, it shows all of the characteristic
features of a functional CpG island (Figure 2) [18,19]. The
distribution of the CpG dinucleotide through this region clusters at
around position +1 (Figure 2A). This region extends for approx.
1.2–1.3 kb, shows a high C + G content (70%) and has a CpG
dinucleotide frequency that is 90% higher than that expected on
the basis of its C + G content (Figure 2B), indicating a very high
CpG island potential [20]. In mammals, DNA methylation occurs
almost exclusively at CpG dinucleotides. A remarkable feature
of CpG islands is that they are refractory to DNA methylation
[18,19]. In contrast, outside of the islands, CpG dinucleotides
are under-represented and mostly methylated. The extent of CpG
methylation through this region was analysed by determining
its sensitivity to cleavage by MspI, which is insensitive to CpG
methylation, in comparison with cleavage by HpaII, which is
sensitive to DNA methylation. As shown in Figure 2(C), in
genomic DNA obtained from Jurkat T-cells, the pattern of MspI
cleavage through this region was very similar to that obtained with
HpaII (Figure 2C, compare lanes 5 and 6), as well as to those
obtained from a BAC clone containing the hPDE7A genomic
region (Figure 2C, lanes 2 and 3). The pattern of digestion by
HpaII shows, however, the presence of bands of higher molecular
mass (Figure 2C, lane 5), which most probably originate from
CpG methylation at the regions surrounding the island. These
results were corroborated when the actual pattern of CpG
methylation through this region was determined by the bisulphite-
conversion reaction (Figure 3) [13]. In denatured DNA, un-
methylated cytosine residues are converted into thymine by the
action of sodium bisulphite. Methylated cytosine is, however,
unreactive to sodium bisulphite. As shown in Figure 3, cytosine-
to-thymine conversion is observed at most CpG dinucleotides
lying within the putative CpG island, indicating that they are
unmethylated. Altogether, these results indicate that the hPDE7A1
5′-flanking region contains a regulatory CpG island.
In Jurkat T-cells, a 2.9-kb fragment of the hPDE7A1 5′-flanking
region has strong promoter activity to which the CpG island
shows an essential contribution
The actual promoter activity of the hPDE7A1 5′-flanking region
described in Figure 1 was determined in transient transfection ex-
periments performed in Jurkat T-cells (Figure 4). In these exper-
iments, different DNA fragments from this region were cloned
into pGL3b plasmid, fused to a luciferase reporter gene. As
shown in Figure 4(A), a DNA fragment extending up to position
−2907 shows strong promoter activity. The luciferase activity
obtained with the −2.9PDE7A construct was 30-fold higher than
that obtained with the promoter-less pGL3b vector carrying no
cloned DNA fragment. A 1.5 kb deletion of the 5′ region of
this fragment, to position −1425, reduced promoter activity to
approx. 60% (Figure 4A, −1.4PDE7A construct). A larger 5′
deletion, to position −988, showed no further effect on promoter
activity (Figure 4A, −0.98PDE7A construct). On the other hand,
the distal 5′ region, from −2900 to −1116, showed no promoter
activity at all by itself (Figure 4A, −2.9PDE7A1.11 construct).
These results show that the proximal region, up to position −988,
contains major cis-regulatory elements of the hPDE7A1 promoter.
Actually, the CpG island described in Figure 2 is contained within
this region, suggesting an essential contribution of this element
to the activity of the hPDE7A1 promoter. Consistent with this
hypothesis, a 5′ deletion to position −560, eliminating the 5′ part
of the CpG island, fully abolished promoter activity (Figure 4A,
Figure 4 Promoter activity of the hPDE7A1 5′-flanking region as determined
in transient-transfection assays performed in Jurkat T-cells using a dual-
luciferase reporter system
(A) Luciferase activities of the promoter constructs indicated on the left are shown. Values are
normalized with respect to the activity of the − 2.9PDE7A construct. (B) Luciferase activities
of promoter constructs lacking the most proximal region, to position − 296 (hatched bars),
are compared with those of the corresponding constructs carrying it (white bars). Values are
normalized with respect to the activity of the − 2.9PDE7A construct. Results correspond to
means +− S.D. from at least six independent experiments.
−0.56PDE7A construct). Similarly, deletion of the 3′ part of
the CpG island also eliminated most of its promoter activity
(Figure 4A, −0.98PDE7A0.56 construct). These results confirm
the fundamental contribution of the CpG island to the regulation
of the activity of the hPDE7A1 promoter. Interestingly, the most
proximal 3′ region of the CpG island shows a higher degree of
methylation (Figure 3), contains a low number of potential binding
sites for transcription factors (Figure 1B) and appears to have a
negative contribution to activation, since, for all the constructs
tested, deletion of the 3′ region to position −296 results in a slight,
though significant, increase in promoter activity (Figure 4B,
−2.9PDE7A0.29, −1.4PDE7A0.29, −0.98PDE7A0.29 and
−0.56PDE7A0.29 constructs).
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Figure 5 In vivo DMS footprinting of hPDE7A1 promoter
(A) Patterns of DMS reactivity of the hPDE7A1 promoter regions indicated (lanes 1–5) were obtained in Jurkat T-cells (lanes marked in vivo) and in naked genomic DNA (lanes marked naked) as
described in the Experimental section. Empty and full triangles indicate hyper- or hypo-reactive residues, respectively. Brackets indicate footprints at binding sites for known transcription factors.
(B) Patterns of in vivo DMS reactivity at the putative NF-κB-binding site occurring at positions − 813 to − 802 obtained after treatment of the cells with 20 nM PMA (lane +) and in the absence
of any stimulation (lane −). The pattern of DMS reactivity of naked genomic DNA is also presented (naked). (C) Summary of the results presented in (A) and (B). Consensus binding sites for
transcription factors showing in vivo footprints are boxed. Arrows correspond to the sets of primers used to analyse by ligation-mediated PCR the various promoter regions.
hPDE7A1 promoter contains three potential CREB-binding sites,
which are occupied in vivo, and is induced by CREB
over-expression
The results reported above confirm the promoter activity of the
CpG island located at the 5′ region flanking the hPDE7A1 gene.
As mentioned above, this region contains potential binding sites
for various transcription factors (Figure 1B) that, characteristic of
most functional CpG islands, lie mainly within the 5′ half of the
island [18,19,21]. Many of the transcription factors that could
potentially bind to this region are known targets of various signal-
ling pathways, suggesting that expression of hPDE7A1 is tightly
regulated. Occupancy of the various potential binding sites for
transcription factors was determined in Jurkat T-cells by in vivo
DMS footprinting (Figure 5). The hPDE7A1 promoter region
contains three cAMP-response elements (CREs; Figure 1B) that
c© 2003 Biochemical Society
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Figure 6 hPDE7A1 promoter is activated by CREB and repressed by KCREB
Luciferase activities of the indicated promoter constructs were determined after co-transfection
with increasing amounts of plasmids expressing CREB (A) or KCREB (B). Values are normal-
ized with respect to those obtained in the absence of any added over-expression plasmid. Results
correspond to means +− S.D. from at least six independent experiments.
are potential binding sites for the CREB family of transcription
factors [22,23]. All three CREs show strong DMS footprints in
vivo (Figure 5A, lanes 1, 4 and 5), indicating that they are actually
occupied, most likely by CREB. Some CREB-binding sites,
however, share significant homology with binding sites for other
transcription factors, such as AP1 or AP2. In fact, in the hPDE7A1
promoter, the distal and proximal CREs also score as potential
AP1 sites, while the intermediate CRE sequence overlaps
with a potential AP2 site (Figure 1B). The actual contribution of
CREB to the regulation of hPDE7A1 promoter was addressed by
transient expression experiments in which hPDE7A1 promoter
constructs were co-transfected to Jurkat T-cells together with
plasmids over-expressing CREB or KCREB, a dominant-
negative mutant form of CREB [15]. As shown in Figure 6,
the −1.4PDE7A construct, which carries all three CREs, is
significantly induced by over-expressing CREB (Figure 6A), but
is repressed when KCREB is over-expressed (Figure 6B). The
−0.98PDE7A promoter construct, carrying only the proximal
CRE, shows similar induction by CREB and repression by
KCREB (Figure 6). Altogether, these results indicate that CREB
contributes to the regulation of hPDE7A1 promoter and strongly
argue in favour of the CREs being functional CREB-binding sites.
In addition to the CREs, distinct footprints are also observed at
a few other regions of the CpG island. In particular, a strong
footprint is observed at position −793 to −768 (Figure 5A,
lanes 3) which includes a potential Sp1-binding site (Figure 5C).
Similarly, a significant footprint is observed at positions −753 to
−747 (Figure 5A, lanes 3), which corresponds to a potential
Ets-2-binding site (Figure 5C). On the other hand, a strong
hyper-reactivity is observed at the putative NFAT-1-binding site
occurring at positions −704 to −697 (Figure 5A, lanes 2). These
results suggest that, in addition to CREB, other transcription
factors are likely to participate in the regulation of hPDE7A1
promoter.
hPDE7A1 promoter is induced by treatment with PMA, but not by
treatment with db-cAMP or forskolin
Inducibility by CREB suggests that hPDE7A1 expression might
be regulated in response to changing intracellular levels of cAMP.
CREB activity is regulated by phosphorylation, principally by
PKA, that is, in turn, the primary target of cAMP stimulation
[22,23]. Actually, in B-lymphocytes, hPDE7A1 expression
was found to be up-regulated by increasing the intracellular
concentration of cAMP [24]. On the contrary, in T-lymphocytes as
well as in Jurkat T-cells, no stimulation of hPDE7A1 transcription
was detected upon treatment of the cells with fenoterol, which
increases intracellular levels of cAMP, or 8-bromo-cAMP [25].
Consistent with these results, in our experimental system, no
significant induction of the hPDE7A1 promoter was observed
when cells were treated with db-cAMP (Figure 7A) or forskolin
(results not shown). Moreover, over-expression of the catalytic
subunit of PKA has no effect on the activity of either the
−1.4PDE7A or −0.98PDE7A promoter constructs (Figure 7B).
It is possible that, in Jurkat T-cells, hPDE7A1 promoter is
constitutively activated by the intracellular pool of functional
CREB. Consistent with this hypothesis, induction of hPDE7A1
promoter showed no synergism when CREB was over-expressed
in cells treated with db-cAMP (results not shown).
On the other hand, a significant increase in the activity of the
hPDE7A1 promoter was observed upon treatment of the cells
with PMA (Figure 7C, −2.9PDE7A construct). Induction by
PMA of the hPDE7A1 promoter is associated mainly with the
CpG island, as shown by the strong induction observed with
promoter constructs containing only this promoter element either
in full or in part (Figure 7C, −0.98PDE7A and −0.56PDE7A
constructs). The most proximal −296 promoter region is,
however, not induced by PMA (Figure 7C, −0.29PDE7A)
and, also in this case, shows a negative contribution to
the activity of the induced promoter. PMA activates protein
kinase C (PKC). CREB can also be phosphorylated by PKC,
and it was proposed that PKC-dependent phosphorylation af-
fects CREB dimerization and activity [26]. Actually, in
lymphocytes, CREB-phosphorylation in response to stimulation
of the B-cell surface immunoglobulin was found to be PKC-
dependent [27]. Therefore, it would be possible that induction
of the hPDE7A1 promoter by PMA would reflect CREB
activation via a PKC-dependent pathway. It is also possible that
induction by PKC of the hPDE7A1 promoter reflects activation
of transcription factors other than CREB. Actually, Ets-2 and
NFAT-1, which, as judged by DMS footprinting (Figure 5A),
are likely to bind the hPDE7A1 promoter in vivo, are known to
be activated by PKC [28,29]. Moreover, upon treatment with
PMA, a distinct footprint is detected at the putative NF-κB-
binding site occurring at positions −813 to −802. In the presence
of PMA, the first guanine of the NF-κB-binding site becomes
hyper-reactive to DMS, while the rest are protected (Figure 5B).
This pattern of DMS reactivity is characteristic of the binding of
NF-κB [30,31], which is also activated by PKC. These observ-
ations might be relevant in the context of T-cell activation, which
involves PKC signalling, and requires induction of hPDE7A
[12]. Moreover, the use of selective inhibitors has revealed the
general contribution of hPDE7 to the regulation of T-cell functions
[32].
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Figure 7 Induction of the hPDE7A1 promoter by treatment with db-cAMP and PMA
The fold induction obtained after treatment for 24 h with 2 mM db-cAMP (A) or 20 nM PMA (C) is presented for the promoter constructs indicated on the left. (B) The effect of over-expressing the
catalytic subunit of PKA on the activity of the indicated promoter constructs. Luciferase activities were determined upon the corresponding treatment and normalized with respect to that of the same
construct obtained in the absence of any treatment. Results correspond to means +− S.D. from four (A) and at least six (B and C) independent experiments.
hPDE7A1 and hPDE7A3 might share a common promoter
hPDE7A isoforms are differentially expressed in some tissues.
hPDE7A1/hPDE7A3 are expressed in lymphoid cells [8,9,11,12]
and, although with different kinetics, they are both induced upon
T-cell activation [9]. On the other hand, hPDE7A2 is predominant
in skeletal muscle and heart [8,10,11]. The promoter region
described here is also likely to drive transcription of the hPDE7A3
isoform, since a single 5′ RACE product was obtained with
primers of the first exon that is common to both hPDE7A1 and
hPDE7A3. Others [9] have reported similar results. The apparent
differences in inducibility and tissue expression observed [9]
could arise from differential splicing regulation or differences
in stability of the transcripts. On the other hand, the transcription
start site of hPDE7A2 isoform was mapped at the second exon of
the hPDE7A gene [10], approx. 50 kb away from the +1 position
of hPDE7A1. Therefore, it is feasible that hPDE7A2 expression
would be driven by a second promoter located at the first intron.
Actually, the contribution of differential promoter usage to the
generation of isoforms has been demonstrated for hPDE5A and
hPDE4D [3,6]. In these cases, an intronic promoter is responsible
for the generation of some of the corresponding variants.
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